Kornimate/medical-research-clean huggingface dataset:
post-traumatic stress, signs of depression and burnout syndrome among nursing home staff in occitanie during the covid-19 pandemic

Conditions: Covid19; Post Traumatic Stress Disorder; Anxiety; Depressive Disorder; Substance Use Disorders

Summary: nursing home staff face multiple stresses during the covid-19 pandemic including personal risk of infection, risk of transmission of the virus to residents and relatives, and risk of witnessing end-of-life scenarios under difficult contexts (absence of families). the hypothesis of this study is that the covid-19 period is associated with an incidence of more than 30% of post-traumatic stress in nursing home staff.


Eligibility criteria:
inclusion criteria: * professional working in a nursing home in occitanie * professional agreeing to participate * professional in a nursing home for at least 3 months * professional able to read french * profession with an internet connection exclusion criteria: * the subject is in a period of exclusion determined by a previous study * the subject refuses to participate * the subject has already been included into the study * it is impossible to give the subject informed information * the subject is under safeguard of justice or state guardianship * the subject is unable to express consent
hobscotch phase iii

Conditions: Epilepsy

Summary: the purpose of this study is to determine the efficacy of an entirely virtual version of the home-based cognitive self-management program "hobscotch." it will test whether hobscotch can be delivered nationally from a distance utilizing e-health tools (telephone, computer, and phone).

hobscotch (home based self-management and cognitive training changes lives) is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. the program is based on problem solving therapy (pst) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life. hobscotch phase iii is a study to examine an entirely virtual version of the program. while hobscotch was shown to be effective as an in-person and telephone-based program in previous trials (hobscotch phase i and ii), this study aims to test a version of the program adapted for entirely virtual delivery. this is a single-center study, with the hobscotch intervention being delivered by staff affiliated with dartmouth-hitchcock medical center in lebanon, nh.

Eligibility criteria:
inclusion criteria: * age 18+ * diagnosis of epilepsy, with controlled or uncontrolled seizures * subjective memory complaints * no changes in antiepileptic and antidepressant medication regimen for 1 month, however brief discontinuation of antiepileptic medicine for inpatient video eeg evaluation is acceptable * literate * telephone access * internet access exclusion criteria: * subjects self-reporting a dementing illness or a mention of a dementing illness in their medical record * severe mental disability or estimated iq less than 70 per clinical judgement * significant visual impairment precluding reading or writing * no reliable telephone or internet access * no diagnosis of epilepsy

Keywords: epilepsy memory problems self-management
intravenous immunoglobulins for post-polio syndrome

Conditions: Post-polio Syndrome

Summary: postpolio syndrome is a condition that affects many polio survivors years after the acute infection and causes symptoms to increase or new symptoms to develop. proinflammatory cytokine production within the central nervous system (cns) indicates an underlying inflammatory process, amenable to immunomodulatory therapy. in this study the investigators sought to confirm that antiinflammatory treatment with intravenous immunoglobulin improves the disease.


Eligibility criteria:
inclusion criteria: * a history of acute poliomyelitis * increased muscle weakness, muscle fatigue and pain in muscle groups previously affected by poliomyelitis * a diagnosis of postpolio syndrome according to the criteria of halstead and rossi exclusion criteria: * clinically relevant systemic disease * malignancy * hypothyroidism * diabetes mellitus not fully controlled by medical therapy * medical or orthopedic disorders that could give rise to symptoms mimicking post-polio syndrome * conditions associated with prolonged coagulation time * serum iga deficiency * previous allergic reaction to ivig * body-mass index greater than 30 * immune-modulating treatments other than ivig within the preceding 6 months
an open-label study for non-responders of vrdn-001-101 and vrdn-001-301 (ole)

Conditions: Thyroid Eye Disease

Summary: an open-label study for participants who received vrdn-001 or placebo and were non-responders at end of the treatment period assessment (i.e., 15 weeks) in the vrdn-001-101 (thrive) and vrdn-001-301 (thrive-2) pivotal studies


Eligibility criteria:
key inclusion criteria: 1. be able to understand the study procedures and the risks involved and be willing to provide written informed consent before the first study-related activity 2. have completed at least 5 iv infusions and assessments required to determine proptosis responder status 3 weeks post the fifth iv infusion (i.e., week 15) as defined in either the vrdn-001-101 or vrdn-001-301 pivotal studies 3. been a participant in either the vrdn-001-101 or vrdn-001-301 studies and found to be a non-responder as defined within the vrdn-001-101 or vrdn-001-301 study 4. not require immediate surgical ophthalmological or orbital surgery in the study eye for any reason 5. must agree to use highly effective contraception as specified in the protocol ⦁ female ted participants must have a negative urine pregnancy test at screening 6. be willing and able to comply with all the requirements of the protocol for the entire duration of the study key exclusion criteria: participants must not: 1. have received prior treatment with another anti-igf-1r agent 2. have received systemic corticosteroids for any condition, including ted, or selenium within 2 weeks prior to first dose 3. have received other immunosuppressive drugs or another investigational agent for any condition, including ted (other than vrdn-001 or placebo associated with the vrdn-001-101 or vrdn-001-301 pivotal studies), or any other therapy for ted, within 8 weeks prior to first dose 4. have received radioactive iodine (rai) treatment within 8 weeks prior to first dose 5. have had previous orbital irradiation or decompression surgery involving excision of fat for ted to the study eye's orbit 6. must not have abnormal hearing test before first dose. must also not have a history of ear conditions considered significant by study doctor

Keywords: graves thyroid-associated ophthalmopathy thyroid eye disease dysthyroid ophthalmopathy graves eye disease graves orbitopathy myopathic ophthalmopathy congestive ophthalmopathy edematous ophthalmopathy infiltrative ophthalmopathy
multiple study of electroaccpuncture in ards

Conditions: Acute Respiratory Distress Syndrome; Sepsis

Summary: in order to clarify the clinical efficacy of electroacupuncture on inhibiting systemic inflammatory response, improving respiratory mechanics parameters and prognosis in patients with sepsis-related ards.


Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria of the surviving sepsis campaign: updated international guidelines for the treatment of sepsis and septic shock 2021 * meet the diagnostic criteria of the european society of critical care medicine (esicm) guidelines for acute respiratory distress syndrome: definition, phenotype and respiratory support strategies * age \>18 years * expected duration of mechanical ventilation\>48 hours * expected icu stay of more than 7 days * signed informed consent. exclusion criteria: * participated in other clinical trials * pregnant, lactating or miscarriage * patients with disseminated tumors or tumors receiving chemotherapy and other special treatments * alcohol abuse * severe cardiovascular, brain, liver, kidney, psychiatric diseases, diabetes, multiple system atrophy, cauda equina injury or myelopathy * systolic blood pressure \< 90mmhg within 2 hours before the start of the study * severe burns or severe skin diseases * pacemaker placement, metal allergy or severe needle sickness * abnormal coagulation function
manual treatment and proprioceptive neuromusculer fasilitation techniques for patients with adhesive capsulitis

Conditions: Adhesive Capsulitis of Shoulder

Summary: this study aim was to compare the effectiveness of manual treatment and proprioceptive neuromuscular fasilitation (pnf) techniques in patients with adhesive capsulitis. one group will receive classical physical therapy including hotpack,ultrason and in additon manual treatment application. other group receive classical physical therapy including hotpack, ultrason and in addition pnf techniques. two group will be made wand exercise at home three times a day 10 times at one session.

there is no consensus physical therapy treatment protocol in adhesive capsulitis. it is because it etiology and pathophysiology is unknown. also it has different clinical stage. pnf techniques often used by physical therapist in adhesive capsulitis aim increasing range of motion, improving muscle strenght and decreasing pain. pnf techniques improves neuromusculer control of central nervous system via stimulating muscle spindles, golgi tendon organs and other receptors in connective tissue. however, there is limited evidence effectivenes of pnf techniques in adhesive capsulitis. other technique often used by physical therapist in adhesive capsulitis is manual treatment. manual treatment decreases pain and improves function. it re-arrange glenohumeral joint arthrocinematic. it diminishes capsule fibrosis. there is no reasearh aimed comparing the pnf and manual treatment. our aim was to compare the effectiveness of manual treatment and pnf techiques in patients with adhesive capsulitis.

Eligibility criteria:
inclusion criteria: * adhesive capsulitis due to idiopathic or acquired reasons exclusion criteria: * cervical disk hernia * neuromusculer disease * shoulder impingement syndrome * rotator cuff tear * corticosteroid enjeksion in shoulder * tumour * physical therapy or manual treatment is implemented same shoulder last 6 months
a phase 1b study to assess the safety, tolerability, and pharmacodynamics of azd4144 in participants with established atherosclerotic cardiovascular and chronic kidney disease.

Conditions: Chronic Kidney Disease; Atherosclerotic Cardiovascular Disease

Summary: the purpose of this study is to evaluate the safety, tolerability and the pharmacodynamics (pd) of azd4144 following oral administration in participants with atherosclerotic cardiovascular disease (ascvd) and chronic kidney disease (ckd).

this is a phase 1b, randomized, double blind, placebo-controlled study and will be conducted in participants with established ascvd and ckd with persistent inflammation (high-sensitivity c-reactive protein \[hscrp\] \> 2 mg/l and eglomerular filtration rate \[egfr\] ≥ 30 to \< 60 ml/min/1.73m2). the participants will be randomized in the 1:1 ratio to either receive treatment with azd4144 or placebo. the study will be comprised of: * a screening period of 28 days * treatment period where each participant will either receive oral dose of azd4144 or placebo for 28 days. * a follow-up visit (day 35 ±1) and a final follow-up (on day 56±1) post first dose administration. the total duration of the study will be approximately 12 weeks.

Eligibility criteria:
key inclusion criteria: * participants with established ascvd history of one or more of the following 1. prior myocardial infarction (mi) (\>60 days from index event) or coronary revascularization procedure like coronary stenting or coronary artery bypass graft (cabg) 2. prior ischemic stroke (\>60 days from index event) 3. symptomatic peripheral arterial disease * chronic kidney disease defined as eglomular filtration rate (egfr) ≥ 30 to \< 60 ml/min/1.73 m2 * serum hscrp \> 2 mg/l * body mass index ≥ 18 to ≤ 45 kg/m2 * all females must have a negative pregnancy test at the screening visit and at the randomization visit 1. sexually active male participants with partner of childbearing potential must adhere to the contraception methods 2. females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception 3. females of non-childbearing potential must be confirmed at the screening visit key exclusion criteria: * history of malignancy within the last 5 years * history of mi, coronary revascularization, stroke or revascularization for peripheral arterial disease in the 60 days prior to screening * active systemic infection within 30 days * clinically significant active and chronic infections within 60 days prior to randomization * clinically significant recurrent infection (≥ 2× during the last 12-month period). * renal transplant participants, participants on dialysis, and those with a history of acute kidney injury in the past 12 month

Keywords: cardiorenal disease estimated glomerular filtration rate nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (nlrp3) cryopyrin inflammatory cytokines
a gray zone approach to stroke volume variation derived from nicom

Conditions: Neurological Diseases or Conditions; Fluid Responsiveness; Non Invasive Cardiac Output Monitoring; Gray Zone

Summary: optimal fluid management has been considered as crucial part to determine postoperative outcome and organ function. recently developed, non invasive cardiac output measurement(nicom, cheetah medical, portland, or)has enabled continuous cardiac output(co) monitoring just by attaching electrode on chest wall. moreover, co and ssv derived from nicom have been demonstrated as predictors of fluid responsiveness. therefore, the aim of this study is to evaluate stroke volume variation derived from nicom as a predictor of fluid responsiveness in neurosurgical patients. in addition, we plan to reveal inconclusive patients using gray zone approach.

optimal fluid management has been considered as crucial part to determine postoperative outcome and organ function. many reports have focussed on evaluation of fluid responsiveness using various parameters such as pulse pressure variation (ppv) or stroke volume variation (ssv) derived from invasive or semi-invasive monitoring. recently developed, non invasive cardiac output measurement(nicom, cheetah medical, portland, or)has enabled continuous cardiac output(co) monitoring just by attaching electrode on thorax. moreover, co and ssv derived from nicom have been demonstrated as predictors of fluid responsiveness. therefore, the aim of this study is to evaluate stroke volume variation derived from nicom as a predictor of fluid responsiveness in neurosurgical patients. in addition, we plan to reveal inconclusive patients using gray zone approach.

Eligibility criteria:
inclusion criteria: * asa i or asa ii patients aged 20-80 undergoing neurosurgery in supine position exclusion criteria: * pre-existing arrythmic disorders * congestive heart failure required medical treatment * preoperative creatinine 1.3mg/dl * observing self respiration during the study interventions * bleeding tendency * severe brain edema

Keywords: neurosurgical patients fluid loading fluid responsiveness nicom stroke volume variation pulse pressure variation total peripheral resistance gray zone approach
proteomics of brain trauma-associated elevated intracranial pressure (icp)

Conditions: Brain Injuries, Traumatic; Traumatic Brain Injury

Summary: the specific aim of this research is to determine if the blood from brain-injured patients contains reproducible protein markers that appear prior to elevations in intracranial pressure (icp).

one of the major causes of death following brain trauma is increased intracranial pressure (icp). currently, there are no effective ways to predict if the icp of a patient will reach uncontrollable levels. various cytokines (balance between pro-and anti-inflammatory) and other factors are thought to underlie increases in icp. the specific aim of this research is to determine if the blood from brain-injured patients contains reproducible protein markers that appear prior to elevations in icp. we propose to employ mass spectrometry, antibody array and elisa to profile proteins in the serum of patients suffering from traumatic brain injury. these protein profiles will be compiled by a pattern recognition program that has the capacity to learn and make predictions based on the spectra and associated patient information. each time a sample is analyzed, it is added to the database allowing the program to make increasingly accurate predictions. protein profiles of patients with known icp values will be analyzed. our hypothesis is that alterations in serum protein composition will precede changes in intracranial pressure giving rise to predictable patterns that can be detected using large-scale proteomic analysis. after approximately 90 non-brain trauma and 90 brain-trauma patients are analyzed, if markers are found, the predictability of elevated icp will be tested. if successful, this may aid the neurosurgeon in determining future courses of treatment.

Eligibility criteria:
inclusion criteria: * 14-65 years old * non-penetrating brain injury * icp monitor or * healthy volunteer or the orthopedic injury cohort will include patients admitted to the ed able to provide informed consent with the following: 1. fracture confirmed radiographically 2. no head trauma 3. no other known inflammatory process or infection 4. no history of neurological or psychiatric disorders or alcohol or drug dependency. or the mild tbi patients will be defined as those experiencing, 1. non-penetrating head trauma manifesting one or more of the following: * loss of consciousness * post-traumatic amnesia * altered mental status * focal neurologic deficits, seizure 2. gcs\> 12 3. no abnormalities on ct other than contusion 4. no operative lesions 5. length of hospital stay \< 48 hrs 6. no other known inflammatory process or infection 7. no history of neurological or psychiatric disorders or alcohol or drug dependency exclusion criteria: * inability to obtain informed consent

Keywords: traumatic brain injury tbi (traumatic brain injury) proteomics
effect of bevacizumab on asymptomatic radiotherapy-induced brain injury

Conditions: Brain Injuries

Summary: to investigate the effect of bevacizumab on asymptomatic radiotherapy-induced brain injury patients with head and neck cancer.

radiotherapy-induced brain injury (ri) is a serious complication of radiotherapy in head and neck cancer (hnc) patients. previous studies have confirmed that bevacizumab has a good effect on patients with symptomatic ri .however, patients with ri maybe do not show clinical symptoms in the early stage. the clinical symptoms will appear with the progression of the ri lesion. there has been no relevant research on whether early intervention is necessary for asymptomatic ri. the investigators conduct this multicenter, randomized clinical research to explore the efficacy and safety of bevacizumab in asymptomatic ri.

Eligibility criteria:
inclusion criteria: head mri confirmed ri lesions. sign the informed consent. exclusion criteria: with clinical symptoms of ri lesions. head mri showed bleeding lesions contraindications of bevacizumab. pregnant women and parturient women.
phase 2 study of ipilimumab in japanese advanced melanoma patients

Conditions: Melanoma

Summary: the purpose of this study is to assess the safety of ipilimumab monotherapy in japanese subjects with advanced melanoma


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * histologically or cytologically confirmed diagnosis of malignant melanoma * previously-treated or untreated unresectable stage iii or stage iv melanoma * measurable/evaluable disease per modified world health organization (mwho) criteria, within 28 days of first dose of study drug * eastern cooperative oncology group (ecog) performance status of 0 or 1 exclusion criteria: * active brain metastases * primary ocular or mucosal melanoma * history of or current active autoimmune disease
tracked ultrasound for patient registration in surgical navigation during abdominal cancer surgery

Conditions: Abdominal Cancer

Summary: the goal of this observational pilot study is to evaluate the feasibility and accuracy of tracked ultrasound registration on patients undergoing abdominal cancer navigation surgery. the main research question is: could tracked ultrasound be applied as an alternative to standard cbct scanning in surgical navigation? participants will undergo tracked ultrasound measurements of the pelvic bone on the operating room after patient anesthesia and before surgical incision.

image-guided navigation surgery allows for full utilization of pre-operative imaging during surgery and has the potential of reducing both irradical resections and morbidity. currently, registration is done by cone-beam ct (cbct) scanning on the operating room (or) prior to navigation surgery. however, standard cbct scanning has several limitations, mainly limited availability on the hybrid or and radiation exposure. furthermore, standard cbct scanning can only be performed in horizontal patient position, while the patient position mostly differs during surgery, such as the trendelenburg position. the use of tracked ultrasound instead of standard cbct could overcome these limitations, which might lead to an increased navigation accuracy and improved surgical outcomes. therefore, the goal of this research is to evaluate the feasibility and accuracy of tracked ultrasound registration on patients undergoing abdominal cancer navigation surgery. the main research question is: could tracked ultrasound be applied as an alternative to standard cbct scanning in surgical navigation?

Eligibility criteria:
inclusion criteria: * age ≥ 18 * patients scheduled for tumor surgery in the abdominal/pelvic area and navigation surgery with a scheduled cbct-scan in the or * patients provide written 'informed consent' exclusion criteria: * no exclusion criteria

Keywords: surgical navigation ultrasound registration electromagnetic tracking pelvic malignancies
a study of rec-1245 in participants with unresectable, locally advanced, or metastatic cancer

Conditions: Unresectable; Locally Advanced; Metastatic Cancers; Relapsed/Refractory Lymphomas

Summary: this is a multi-center, open-label study to investigate the safety, tolerability, pk, pd, and preliminary activity of rec-1245 administered orally on a once daily (qd) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.

approximately 85 individuals will be enrolled in this open-label phase 1/2 study, allocated 55 individuals in phase 1 and 10-30 individual's in phase 2. the purpose of this study is to investigate the safety, tolerability and pharmacokinetics of rec-1245 for the treatment of participants with unresectable locally advanced or metastatic solid tumors. participants will receive treatment with rec-1245 for up to 2 years.

Eligibility criteria:
inclusion criteria: * 18 years or older have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy. ecog performance status ≤ 1 measurable disease at baseline per recist 1.1 / lugano criteria and documented by computed ct and / or mri exclusion criteria: * received treatment with another rbm39 degrader clinically significant gastrointestinal (gi) or gi malabsorption

Keywords: rbm39 cancer refractory lymphomas metastatic cancers